论文部分内容阅读
目的:研究非小细胞肺癌(NSCLC)患者肿瘤组织中β-微管蛋白-Ⅲ(β-tubulin-Ⅲ)基因的表达与患者对长春碱类药物化疗敏感性的关系,为患者选择适当的药物治疗提供依据。方法:共入选35例NSCLC患者,随机分入长春瑞滨(NVB)联合顺铂(PDD)或卡铂(CBP)组成NP方案化疗组和吉西他滨(GEM)联合PDD或CBP组成GP方案组,观察两组对化疗的反应;同时以RT-PCR法检测患者病理组织中β-tubulin-ⅢmRNA的表达,以Westernblot检测β-tubulin-Ⅲ蛋白的含量。结果:NP组19例,GP组16例,两组患者临床特点无明显差别,对化疗总的有效率相似,在NP组内,有效10例,无效9例,有效患者的肿瘤组织中β-tubulin-Ⅲ mRNA测量值为4.8±1.9,而无效患者为15.8±8.0,两者有显著性差异(P<0.01);有效患者β-tubulin-Ⅲ蛋白的测量值为3.7±1.5,无效患者为13.5±6.2(P<0.01)。GP组7例无效,9例有效,有效与无效患者肿瘤组织中β-tubulin-Ⅲ mRNA和β-tubulin-Ⅲ蛋白表达均无显著性差异(P>0.05)。结论:NSCLC患者肿瘤组织中β-tubulin-Ⅲ基因的表达与患者对长春碱类药物的敏感性有关,β-tubulin-Ⅲ基因高表达,提示对长春碱类药物的敏感性低,宜换用其他药物治疗。
OBJECTIVE: To investigate the relationship between the expression of β-tubulin-Ⅲ gene and the sensitivity of patients to vinblastine chemotherapy in non-small cell lung cancer (NSCLC) patients and to select appropriate drugs Provide the basis for treatment. Methods: A total of 35 patients with NSCLC were enrolled and randomized into GP regimen consisting of NPB combined with cisplatin (PDD) or carboplatin (NP) chemotherapy and gemcitabine (GEM) combined with PDD or CBP. The response of two groups to chemotherapy was evaluated. The expression of β-tubulin-ⅢmRNA in pathological tissues was detected by RT-PCR, and the content ofβ-tubulin-Ⅲprotein was detected by Western blot. Results: There were 19 cases in NP group and 16 cases in GP group. There was no significant difference in clinical features between the two groups. The total effective rate was similar in chemotherapy group. In NP group, 10 cases were effective and 9 cases were ineffective. The measured value of tubulin-Ⅲ mRNA was 4.8 ± 1.9, while that of ineffective patients was 15.8 ± 8.0, with significant difference (P <0.01). The measured value of β-tubulin-Ⅲ protein in effective patients was 3.7 ± 1.5, 13.5 ± 6.2 (P <0.01). There was no significant difference in the expression of β-tubulin-Ⅲ mRNA and β-tubulin-Ⅲ protein in 7 cases of GP group and 9 cases of effective, ineffective and ineffective tumor tissues (P> 0.05). CONCLUSIONS: The expression of β-tubulin-Ⅲ gene in NSCLC patients is related to the sensitivity of patients to vinblastine. The high expression of β-tubulin-Ⅲ gene suggests that the sensitivity to vinblastine is low and should be changed Other medical treatment.